上海医药未来当不会让市场失望上海医药终于从绵延4个多月的负面传闻中挣脱。7月16日,上海医药召开投资者大会,向投资者一一介绍高管团队及经营情况,其态度恳切,为其恢复形象大为增分。7月17日,H股上涨1.87%,7月18日,在整体大盘弱势中,其A股仍上涨1.2%回应。7月20日,H股上涨幅度高达5.37%。市场亦接纳了风波后的上海医药。6月以来,多家券商的研究报告对上海医药首做“增持”评级。“财务造假风波基本结束,我们对上海医药诚信的基本信心得到确认。”国泰君安的行业分析报告表示。中金公司则直言不讳地表明态度:“我们认为现在的管理层已走到了 Shanghai Pharmaceutical future will not let the market down Shanghai Pharmaceutical finally broke loose from more than 4 months of negative rumors. On July 16, Shanghai Pharmaceutical held an investor conference to brief investors on the top management team and its operations. The attitude of the company was sincere and greatly increased its recovery image. July 17, H shares rose 1.87%, July 18, in the broader market weakness, its A shares are still up 1.2% response. July 20, H shares rose as much as 5.37%. Shanghai Pharmaceutical also accepted the turmoil after the market. Since June, a number of brokerages research report on the Shanghai Pharmaceutical first ”overweight“ rating. ”Financial fraud is basically over, we confirm the basic confidence of Shanghai Pharmaceutical integrity. “ Guotai Junan industry analysis report said. CICC is outspoken to show their attitude: ”We think that the management has now come